Fig. 7.

Overview of subtype-specific prognostic power of glypicans in breast cancer. Summary of key results of the present study. For overall breast cancer patients, that have not been classified by receptor status, higher levels of GPC3 are associated with longer RFS. If patients are stratified by receptor status, GPC6 is a prognostic marker for subtypes that have an initially better prognosis. Low GPC6 levels are correlated with a longer RFS. GPC1 is a prognostic marker for initially worse prognosis subtypes, and low levels of the glypican are associated with longer RFS. Adapted from “Intrinsic and Molecular Subtypes of Breast Cancer”, by BioRender.com (2020) and created in PowerPoint. Retrieved from https://app.biorender.com/biorender-templates